This year’s LESI conference focused on how licensing executives can best commercialise IP in a time of rapid technological change.
Andy Richards, a biotechnology entrepreneur and chairman and director of various Cambridge-based biotechnology companies, chaired a panel that looked at the challenges facing 21st century life sciences companies.
Richards said that many of the new technologies being invented do not fit current licensing business models. The life sciences market is further complicated by companies such as Google and Microsoft entering a market (through research funding) already populated by mainstays such as GE.
New business ventures from emerging markets may add to this because it is unclear “what form those will take”, he said.
LESI conference 2011, life sciences, technology